Mitigate risks in clinical trials

Potentially valid drugs are sometimes denied FDA approval because flawed clinical data undermines efficacy and safety findings, says Health Decisions. The company notes that risk is at an all-time high in clinical development. In a new white paper, the group describes factors that make some trials riskier than others, as well as systematic risk mitigation. Release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.